| Literature DB >> 20454535 |
Abstract
The present study was designed to evaluate the influence of alpha-lipoic acid treatment in rats exposed to malathion. Forty adult male rats were used in this study and distributed into four groups. Animals of group 1 were untreated and served as control. Rats of group 2 were orally given malathion at a dose level of 100 mg/kg body weight (BW) for a period of one month. Experimental animals of group 3 were orally given alpha-lipoic acid at a dose level of 20 mg/kg BW and after 3 hours exposed to malathion at the same dose given to group 2. Rats of group 4 were supplemented with alpha-lipoic acid at the same dose given to group 3. The activities of serum glutamic oxaloacetic acid transaminase (GOT), glutamic pyruvic acid transaminase (GPT), alkaline phosphatase (ALP), and acid phosphatase (ACP), and the values of creatinine, urea, and uric acid were statistically increased, while the values of total protein and total albumin were significantly decreased in rats exposed to malathion. Moreover, administration of malathion for one month resulted in damage of liver and kidney structures. Administration of alpha-lipoic acid before malathion exposure to rat can prevent severe alterations of hemato-biochemical parameters and disruptions of liver and kidney structures. In conclusion, this study obviously demonstrated that pretreatment with alpha-lipoic acid significantly attenuated the physiological and histopathological alterations induced by malathion. Also, the present study identifies new areas of research for development of better therapeutic agents for liver, kidney, and other organs' dysfunctions and diseases.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20454535 PMCID: PMC2864892 DOI: 10.1155/2010/203503
Source DB: PubMed Journal: J Biomed Biotechnol ISSN: 1110-7243
Figure 1The chemical structure of α-lipoic acid.
Changes in values of serum GOT, GPT, ALP, ACP, total protein, total albumin, creatinine, urea, and uric acid in rats treated with malathion, malathion plus α-lipoic acid, and α-lipoic acid. Tabulated values are means of ten determinations ± standard deviation (SD).
| Parameters | Treatment | |||
|---|---|---|---|---|
| Control | Malathion | Malathion + | ||
| GOT (UL−1) | 61.80 ± 3.29 | 189.40 ± 13.62a,b | 115.30 ± 5.8a | 56.70 ± 6.52 |
| GPT (UL−1) | 39.50 ± 3.17 | 112.70 ± 9.99a,b | 64.30 ± 7.84a | 38.20 ± 2.52 |
| ALP (UL−1) | 324.40 ± 10.86 | 632.70 ± 29.89a,b | 395.30 ± 37.05a | 339.20 ± 20.61 |
| ACP (UL−1) | 109.80 ± 9.25 | 166.40 ± 27.69a,b | 139.30 ± 17.17a | 114.20 ± 13.58 |
| Total protein (g 100 mL−1) | 6.75 ± 0.28 | 5.51 ± 0.30a,b | 6.64 ± 0.38 | 6.73 ± 0.28 |
| Total albumin (g 100 mL−1) | 3.18 ± 0.19 | 2.86 ± 0.20a,b | 3.13 ± 0.23 | 3.24 ± 0.25 |
| Creatinine (mg 100 mL−1) | 0.67 ± 0.05 | 1.16 ± 0.24a,b | 0.82 ± 0.11a | 0.70 ± 0.08 |
| Urea (mg 100 mL−1) | 23.56 ± 1.77 | 30.12 ± 2.45a,b | 25.28 ± 1.92 | 22.74 ± 2.04 |
| Uric acid (mg 100 mL−1) | 3.71 ± 0.27 | 4.90 ± 0.47a,b | 4.01 ± 0.36 | 3.86 ± 0.26 |
a: Indicates a significant difference between control and treated groups.
b: Indicates a significant difference between the group treated with malathion and groups treated with malathion plus α-lipoic acid and α-lipoic acid.
Figure 2Liver micrographs of control (a), malathion ((b) and (c)), and malathion plus α-lipoic acid (d) treated rats. Original magnification X400.
Figure 3Renal corpuscle micrographs of control (a), malathion ((b) and (c)), and malathion plus α-lipoic acid (d) treated rats. Original magnification X400.